The latest biotech news

News and Trends 17 Feb 2023

Avilar Therapeutics financing up to $75M to boost extracellular protein degraders pipeline

Avilar Therapeutics has raised additional funding with an expanded syndicate of new investors to support advancing a pipeline of first-in-class extracellular protein degraders. The new financing takes the company’s total to $75 million. The seed round had initial funding from Avilar’s founding investor, RA Capital Management, and now includes participation by new investors Sanofi Ventures, […]

February 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 17 Feb 2023

Report: China leads the way with phase 1 studies

Novotech, an Asia Pacific biotech CRO, has published a new global report on phase 1 trial activity including current metrics on fast growth regions and therapeutic areas. The data analysis found that Asia Pacific has been the fastest-growing region for phase 1 clinical trials in the last 10 years, reaching a share of 58% in […]

February 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 17 Feb 2023

Beyond Biotech podcast 34: eClinical Solutions, GPCR Therapeutics, Orbsen Therapeutics

Our Beyond Biotech podcast 34 guests are Katrina Rice, chief delivery officer, biometrics services at eClinical Solutions; Pina Cardarelli, president and CSO of GPCR Therapeutics; and Larry A Couture, CEO of Orbsen Therapeutics. GPCR Therapeutics launches multiple myeloma trial GPCR Therapeutics, Inc., a drug discovery company targeting G Protein Coupled Receptors (GPCR) pairs, recently started […]

February 17, 2023

News and Trends 16 Feb 2023

Newron reports ‘striking’ schizophrenia study results

Newron Pharmaceuticals S.p.A. has announced what it says are ‘very exciting new results’ from the first 100 randomized patients who have completed one year of treatment in its study of evenamide as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe treatment-resistant schizophrenia (TRS) not responding to their current antipsychotic medication. […]

February 16, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 16 Feb 2023

Maxion Therapeutics raises $16M to target GPCRs

Biotechnology company Maxion Therapeutics has completed its $16 million Series A financing. The funds will be used to support the development of novel biologics targeting ion channels and G-protein-coupled receptors (GPCRs) via Maxion’s proprietary, patent-protected KnotBody platform. Ion channels and GPCRs are critical cell surface proteins involved in a wide range of previously untreatable or […]

February 16, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 16 Feb 2023

Bladder cancer investigational therapy may be given at home

UroGen Pharma Ltd. has announced preliminary results of a study to assess the feasibility of home instillation of UGN-102 (mitomycin) for intravesical solution, an investigational therapy in development for primary chemoablation of low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). In the study, UGN-102 was suitable to administer at home by a visiting nurse under the […]

February 16, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 16 Feb 2023

Genetic study reveals high variation in T-cell receptor genes

T-cells are central in the protection against infections and cancer. With the help of TCRs (T-cell receptors), cells recognize foreign invaders and tumor cells. “It was previously unknown how variable human TCR genes are,” said Gunilla Karlsson Hedestam, professor at the department of microbiology, tumor and cell biology at Karolinska Institutet in Sweden, and the […]

February 16, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 16 Feb 2023

Cytovation melanoma study under way

Cytovation ASA, a Norwegian clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane immunotherapy, announces that the first patient has been dosed in its phase 2a study. The trial is investigating CyPep-1 monotherapy in patients with advanced melanoma refractory to checkpoint inhibitors (CPIs). The study is an expansion arm […]

February 16, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 16 Feb 2023

Lipid fingerprint could help TB treatment

A new method that measures the amounts of drugs and lipids in individual cells could help health professionals target more effective treatments for diseases such as tuberculosis (TB). Researchers from the University of Surrey in the U.K. were able to isolate individual living cells that contained drugs commonly used to treat tuberculosis and found that […]

February 16, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 14 Feb 2023

Disc Medicine raises $62.5M for hematology programs

Disc Medicine, Inc., a U.S. clinical-stage biopharma company focused on the discovery, development and commercialization of treatments for patients suffering from serious hematologic diseases, has entered into a securities purchase agreement with investors resulting in an aggregate $62.5 million in gross proceeds through a registered direct offering. The financing was led by Bain Capital Life […]

February 14, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 14 Feb 2023

Scancell looking to partner after positive COVID vaccine data

Scancell Holdings plc, which develops novel immunotherapies for the treatment of cancer and infectious disease, has announced preliminary immunogenicity data from its phase 1 COVIDITY clinical trial at the University of Cape Town (UCT) Lung Institute in South Africa. The objectives of the trial were to assess the safety and immunogenicity of two vaccine candidates, […]

February 14, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 14 Feb 2023

Syena created to deliver first-in-class TCR-NK cell therapy

Replay, a genome writing company reprogramming biology by writing and delivering big DNA, and The University of Texas MD Anderson Cancer Center, have launched Syena, a new oncology-focused product company pioneering T-cell receptor (TCR) natural killer (NK) cell therapies (TCR-NKs). Building on the intellectual property and technology from MD Anderson and Replay, Syena has the […]

February 14, 2023 - 4 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Avilar Therapeutics financing up to $75M to boost extracellular protein degraders pipeline

Report: China leads the way with phase 1 studies

Beyond Biotech podcast 34: eClinical Solutions, GPCR Therapeutics, Orbsen Therapeutics

Newron reports ‘striking’ schizophrenia study results

Maxion Therapeutics raises $16M to target GPCRs

Bladder cancer investigational therapy may be given at home

Genetic study reveals high variation in T-cell receptor genes

Cytovation melanoma study under way

Lipid fingerprint could help TB treatment

Disc Medicine raises $62.5M for hematology programs

Scancell looking to partner after positive COVID vaccine data

Syena created to deliver first-in-class TCR-NK cell therapy

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!